Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin

Dominic Fan, Seiji Yano, Hisashi Shinohara, Carmen Solorzano, Melissa Van Arsdall, Corazon D. Bucana, Sen Pathak, Ewa Kruzel, Roy S. Herbst, Amir Onn, Jennifer S. Roach, Masanori Onda, Qing Cheng Wang, Ira Pastan, Isaiah J. Fidler

Research output: Contribution to journalArticlepeer-review

Abstract

Several tumors, including mesothelioma and ovarian cancer, can overexpress mesothelin, a glycosylphosphatidylinositol-linked differentiation glycoprotein. The membrane-bound type of mesothelin is found in the blood of cancer patients at a very low level, which makes mesothelin a good candidate for targeted therapy of certain cancers. An antimesothelin disulfide-linked Fv (SS1 Fv) was fused to a truncated mutant of Pseudomonas exotoxin A to produce the recombinant immunotoxin SS1(dsFv)-PE38, which has a high binding affinity to mesothelin (Kd = 0.7 nM). Our studies in vitro showed that SS1(dsFv)-PE38 is significantly more cytotoxic to the high-mesothelinproducing NCI-H226 human non-small cell lung cancer cells than to human lung adenocarcinoma PC14PE6 cells, which do not express mesothelin. When administered at a nontoxic dose of 500 μg/kg on days 7, 9, and 11 to nude mice injected i.v. with the two human lung cancer cell lines, SS1(dsFv)-PE38 selectively inhibited experimental lung metastases produced by the mesothelin-producing NCI-H226 cells. Our data indicate that mesothelin-producing squamous cell carcinoma of the lung may be a good target for this immunotoxin.

Original languageEnglish
Pages (from-to)595-600
Number of pages6
JournalMolecular Cancer Therapeutics
Volume1
Issue number8
StatePublished - Jun 2002
Externally publishedYes

Fingerprint

Dive into the research topics of 'Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin'. Together they form a unique fingerprint.

Cite this